Overview

Recombinant Anti-tumor and Anti-virus Protein for Injection Plus Xeloda in Treatment of Metastatic Colorectal Cancer

Status:
Unknown status

Trial end date:
2016-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy and safety of recombinant anti-tumor and anti-virus protein for injection plus capecitabine in treating patients with metastatic colorectal cancer who have progressed after standard therapy.

Phase:

Phase 2

Details

Lead Sponsor:

The Affiliated Hospital of the Chinese Academy of Military Medical Sciences

Treatments:

Capecitabine